Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.03 and traded as high as $6.86. Tenax Therapeutics shares last traded at $6.75, with a volume of 33,111 shares traded.

Tenax Therapeutics Stock Up 10.1 %

The firm’s 50-day moving average is $6.38 and its two-hundred day moving average is $5.04.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC acquired a new stake in Tenax Therapeutics during the 3rd quarter worth $173,000. Vestal Point Capital LP acquired a new stake in Tenax Therapeutics during the 3rd quarter worth $288,000. Sphera Funds Management LTD. acquired a new stake in Tenax Therapeutics during the 3rd quarter worth $101,000. Geode Capital Management LLC grew its holdings in Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics in the 4th quarter valued at $1,026,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.